FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025859766> ?p ?o ?g. }

• W2025859766 endingPage "8274" @default.
• W2025859766 startingPage "8268" @default.
• W2025859766 abstract "The need for worldwide seasonal and pandemic vaccine production has increased interest in the development of innovative technologies for influenza vaccine production. We evaluated a novel influenza vaccine consisting of the globular head of the HA1 domain of the A/Solomon Islands/3/2006 (H1N1) influenza virus (VAX125) genetically fused to the TLR5 ligand, flagellin, and produced in E. coli.128 healthy adult subjects 18-49 years old were enrolled in a clinical trial conducted in three stages at a single center. Stage 1 was an open-label, dose escalation study in which the VAX125 vaccine was administered intramuscularly (im) at doses of 0.1 μg, 0.3 μg, 1 μg, 2 μg, 3 μg, 5 μg and 8 μg to groups of 8 subjects each. Stage 2 was a double-blind, placebo-controlled study in which subjects were randomized to receive 1.0 μg and 2.0 μg VAX125 vaccine doses or placebo, with 16 subjects per group. Finally, an additional 24 subjects received a 0.5 μg dose of VAX125 in stage 3, which was a non-randomized, open label study. In all parts subjects were followed for adverse events and sera was tested by hemagglutination-inhibition (HAI) and microneutralization (MN) against egg-grown virus on days 0, 7, 14, and 28. Serum C-reactive protein (CRP), cytokine levels, and anti-flagellin antibody were also assessed.Vaccine was generally well tolerated and there were no serious adverse events. Pain at the injection site was the most common local adverse event, and was mild or moderate in intensity. Systemic symptoms after vaccination include fatigue and headache, and two subjects, who received either 3 or 8 μg, had moderately severe systemic symptoms accompanied by substantial increases in serum CRP. Serum antibody responses against SI were seen by HAI and MN in most study subjects, with the geometric mean titer of post vaccination antibody increasing in a dose-dependent fashion. Overall, four-fold or greater serum HAI responses were seen in 61 of 96 (64%) subjects who received doses of 0.5 μg or greater, including in 46 of 72 subjects who received doses from 0.5 μg to 2 μg.The globular head of the influenza HA expressed in a prokaryotic system was able to induce a functional antibody response against native virions. Vigorous responses were seen at relatively low doses of HA antigen suggesting that the addition of flagellin provided a substantial adjuvanting effect. The high levels of immune response at low doses of antigen and the relative ease of production associated with E. coli expression suggests that this approach may represent an effective strategy for enhancing the global influenza vaccine supply." @default.
• W2025859766 created "2016-06-24" @default.
• W2025859766 creator A5001805971 @default.
• W2025859766 creator A5006389719 @default.
• W2025859766 creator A5007460950 @default.
• W2025859766 creator A5025081762 @default.
• W2025859766 creator A5032351782 @default.
• W2025859766 creator A5054539574 @default.
• W2025859766 creator A5055694413 @default.
• W2025859766 creator A5064376545 @default.
• W2025859766 creator A5067329211 @default.
• W2025859766 creator A5083732628 @default.
• W2025859766 creator A5087728228 @default.
• W2025859766 date "2010-12-01" @default.
• W2025859766 modified "2023-10-01" @default.
• W2025859766 title "Safety and immunogenicity of a recombinant hemagglutinin influenza–flagellin fusion vaccine (VAX125) in healthy young adults" @default.
• W2025859766 cites W1519633296 @default.
• W2025859766 cites W1969471820 @default.
• W2025859766 cites W1975654823 @default.
• W2025859766 cites W2007041007 @default.
• W2025859766 cites W2024238985 @default.
• W2025859766 cites W2039820433 @default.
• W2025859766 cites W2048521619 @default.
• W2025859766 cites W2058144955 @default.
• W2025859766 cites W2065420324 @default.
• W2025859766 cites W2068920418 @default.
• W2025859766 cites W2070785963 @default.
• W2025859766 cites W2081546595 @default.
• W2025859766 cites W2097045245 @default.
• W2025859766 cites W2098084836 @default.
• W2025859766 cites W2107587363 @default.
• W2025859766 cites W2139841187 @default.
• W2025859766 cites W2155467153 @default.
• W2025859766 doi "https://doi.org/10.1016/j.vaccine.2010.10.009" @default.
• W2025859766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20969925" @default.
• W2025859766 hasPublicationYear "2010" @default.
• W2025859766 type Work @default.
• W2025859766 sameAs 2025859766 @default.
• W2025859766 citedByCount "123" @default.
• W2025859766 countsByYear W20258597662012 @default.
• W2025859766 countsByYear W20258597662013 @default.
• W2025859766 countsByYear W20258597662014 @default.
• W2025859766 countsByYear W20258597662015 @default.
• W2025859766 countsByYear W20258597662016 @default.
• W2025859766 countsByYear W20258597662017 @default.
• W2025859766 countsByYear W20258597662018 @default.
• W2025859766 countsByYear W20258597662019 @default.
• W2025859766 countsByYear W20258597662020 @default.
• W2025859766 countsByYear W20258597662021 @default.
• W2025859766 countsByYear W20258597662022 @default.
• W2025859766 countsByYear W20258597662023 @default.
• W2025859766 crossrefType "journal-article" @default.
• W2025859766 hasAuthorship W2025859766A5001805971 @default.
• W2025859766 hasAuthorship W2025859766A5006389719 @default.
• W2025859766 hasAuthorship W2025859766A5007460950 @default.
• W2025859766 hasAuthorship W2025859766A5025081762 @default.
• W2025859766 hasAuthorship W2025859766A5032351782 @default.
• W2025859766 hasAuthorship W2025859766A5054539574 @default.
• W2025859766 hasAuthorship W2025859766A5055694413 @default.
• W2025859766 hasAuthorship W2025859766A5064376545 @default.
• W2025859766 hasAuthorship W2025859766A5067329211 @default.
• W2025859766 hasAuthorship W2025859766A5083732628 @default.
• W2025859766 hasAuthorship W2025859766A5087728228 @default.
• W2025859766 hasConcept C126322002 @default.
• W2025859766 hasConcept C136449434 @default.
• W2025859766 hasConcept C142724271 @default.
• W2025859766 hasConcept C159047783 @default.
• W2025859766 hasConcept C159654299 @default.
• W2025859766 hasConcept C170493617 @default.
• W2025859766 hasConcept C182072434 @default.
• W2025859766 hasConcept C197934379 @default.
• W2025859766 hasConcept C203014093 @default.
• W2025859766 hasConcept C204787440 @default.
• W2025859766 hasConcept C22070199 @default.
• W2025859766 hasConcept C2522874641 @default.
• W2025859766 hasConcept C27081682 @default.
• W2025859766 hasConcept C2776709828 @default.
• W2025859766 hasConcept C2777338127 @default.
• W2025859766 hasConcept C2777546802 @default.
• W2025859766 hasConcept C2777704310 @default.
• W2025859766 hasConcept C2778692840 @default.
• W2025859766 hasConcept C2780689484 @default.
• W2025859766 hasConcept C2780868878 @default.
• W2025859766 hasConcept C32611913 @default.
• W2025859766 hasConcept C38117629 @default.
• W2025859766 hasConcept C71924100 @default.
• W2025859766 hasConcept C8891405 @default.
• W2025859766 hasConceptScore W2025859766C126322002 @default.
• W2025859766 hasConceptScore W2025859766C136449434 @default.
• W2025859766 hasConceptScore W2025859766C142724271 @default.
• W2025859766 hasConceptScore W2025859766C159047783 @default.
• W2025859766 hasConceptScore W2025859766C159654299 @default.
• W2025859766 hasConceptScore W2025859766C170493617 @default.
• W2025859766 hasConceptScore W2025859766C182072434 @default.
• W2025859766 hasConceptScore W2025859766C197934379 @default.
• W2025859766 hasConceptScore W2025859766C203014093 @default.
• W2025859766 hasConceptScore W2025859766C204787440 @default.
• W2025859766 hasConceptScore W2025859766C22070199 @default.

• next